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Immunohistochemical detection of antigen distribution within infected formalin-fixed 
paraffin-embedded (FFPE) tissues is an extremely specific and complex procedure that is still 
relatively new in diagnostic pathology. New and improved techniques that aid to improve the 
sensitivity and specificity of an immunohistochemical (IHC) test are required for a more accurate 
etiologic diagnosis. The objective of this research study was to evaluate IHC protocol 
development techniques and procedures on FFPE biological tissues to improve biomolecular 
antibody-antigen detection using chromogenic enzymes. This study provides evidence 
suggesting that multiple factors play a significant role on the outcome of an accurate IHC test; 
pH and purified antibody concentration being among the most prominent. In addition, 
diminishing testing development associated costs, while reducing diagnostic turn-around time is 
attainable through a standardized approach to the protocol development process, resulting in 
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The efficacy of IHC as a diagnostic tool is determined by the accurate protocol 
development according to the antigen characteristics of the infectious agent. There is no 
uniformity to IHC testing, each test must be specifically designed based on the characteristics of 
the identifying agent. The protocol process is one of the major pitfalls when utilizing IHC as a 
tool for diagnosis, it can be time consuming and costly while producing false positive results due 
to multifaceted steps and insufficient reference material pertaining to the subject.    
New and improved IHC development standardization techniques may eliminate 
superfluous steps in the development process, reducing cost and diagnosis time while increasing 
overall reliability of IHC as a diagnostic tool. Biomolecular detection is a complex and sensitive 
technique that requires the knowledge of a trained pathologist to interpret morphology of 
biological tissues in association with an infectious agent or a disease. IHC interpretation is 
qualitative by nature and greatly dependent on the subjective analysis of pathological etiology 
and agent characteristics, resulting in associated vulnerabilities to false interpretation which is 
exacerbated by inadequate IHC staining quality. Ensuring quality and efficiency of IHC staining 
as an informative diagnostic tool, comprises solely on the protocol development process.   
Diminishing background staining due to non-specific binding of primary and secondary 
antibodies, while improving signal amplification at antibody-antigen binding motifs are crucial 
for reducing inaccurate interpretation by pathologists. Improved IHC development methods will 
also aid in dual biomarker immunolabelling, which provides additional information on biomarker 
co-localization expression patterns within tissues matrices. 
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Chapter 1 - Literature Review 
 1.1 IHC staining 
Immunohistochemistry (IHC) is a laboratory method that utilizes antibodies to detect and 
bind to antigens within biologically preserved tissues that have undergone a fixation process to 
immobilize protein structures. The antibody-antigen interaction is microscopically visualized 
through a colorimetric reaction of a chromogen substrate and an enzyme-labeled catalyst, 
producing a color precipitate at the location of a biomolecular target, displaying distribution 
and/or localization expression patterns of protein antigens in sample tissues (Abcam, 2019).   
The two methods of IHC staining are characterized as direct and indirect.  A direct IHC 
method is based on an enzyme-conjugated primary antibody and is generally utilized when 
biomarker antigen expression is pre-determined as abundant (Abcam, 2019). The indirect IHC 
method is the most common technique of IHC agent detection as it associates enhanced signal 
expression with low antigen load, making it indispensable in the detection of unknown or novel 
biomarkers within biological tissues. Indirect IHC detection is based off an initial un-labelled 
primary antibody that binds to a target antigen and signal amplification is enhanced with a 
secondary labelled antibody that must be raised against the host species of the un-labelled 
primary antibody, focusing on immunoglobulin isotype and if available, subtype (Abcam, 2019).  
Pathological diagnosis is established through predetermined knowledge of the location of 
a target molecule and their immunoreactivity pattern. From this an investigator is able to 
determine if the microanatomic and cellular distribution of an antigen is a match for a disease 
(Matos, Trufelli, & Pinhal, 2010).  
IHC is used to detect infectious agents as well as cancer specific tumor antigens, through 
specificity and sensitivity of monoclonal and polyclonal antibody-antigen interactions. This 
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demonstrates the effectiveness of IHC as a reliable laboratory diagnostic method for determining 
the etiology of a disease, cytogenesis of a neoplasm or elucidating the pathogenesis of a disease 
process (Ramos-Vara et al., 2008). 
The first IHC stain was developed in 1941. However, the field of IHC is in continuous 
development due to novel and emerging infectious diseases and/or mutations within the genome 
of established diseases. In recent years, its application is extended for a number of laboratory 
immunohistochemical tests designed specifically for the detection of neoplastic and infectious 




Figure 1 Biomechanical depiction of indirect IHC staining for detection of infectious agents 




 1.2 Process and Challenges of indirect IHC 
IHC staining by nature is vulnerable to multiple variables, hence the multifaceted 
approaches to the protocol development process. The lack of standardization addressing these 
drawbacks result in delayed or inconsistent experimental test results. Obtaining true-positive test 
results requires fundamental knowledge of the target proteins, as well as delineating foundational 
steps to eliminate unnecessary functions in the developmental stages of target design. 
 
Figure 2 Essential steps in the indirect IHC staining process 
 
Step 1 – Ensure proper fixation of sample tissues, with 24–48-hour fixation time with a 
sample to fixative ratio of 1:10 respectively (KSVDL, 2021).  Improper fixation of tissues will 
produce non-specific binding from endogenous proteins while presenting possible biosafety 
concerns. Over-fixed tissues will make antigen retrieval difficult due to extensive protein cross-
linking within the tissue matrix which occurs when exposed to a formalin-fixative, resulting in 
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loss of antigen detection over-time. (Scalia et al., 2017). Complete tissue infiltration of paraffin 
wax immobilizes the fixed tissues for sectioning on a microtome. 
Step 2- Use high quality sections cut at 4 microns and thoroughly dry onto a charged 
slide. If the section is uneven, displays ribboning, is poorly adhered or retains water, sectioning 
artifacts will occur, yielding variable staining (Geoffrey, Westra, Steven, Anderson, & James 
2019).  
Step 3- Ensuring de-paraffinization and preparation of tissue samples is essential, if 
existing paraffin resides within the tissue matrix, weak to no staining will occur. 
Step 4- Antigen Retrieval (AR) is one of the critical steps in ensuring antigen detection 
and overall IHC success, choosing the appropriate AR method for conserved epitope exposure in 
tissues that have undergone tissue preservation is imperative due to the hypersensitivity of the 
biomolecular exposure process. pH, reagent, and reaction conditions all influence the success of 
antigen retrieval, the most common method being Heat Induced Epitope Retrieval (HIER).  The 
proper AR solution and its pH must be determined with consideration of appropriate temperature 
and incubation time.  
Step 5- Blocking endogenous enzymes such as peroxidase, found primarily in liver, 
kidney and spleen tissues and Alkaline phosphatase (AP), typically present in kidney, intestine, 
lymphoid and placental tissues, is key to reducing non-specific binding, leading to a potential 
false-positive diagnosis (Chen, Cho, & Yang, 2010). The reason behind blocking endogenous AP 
and peroxidase stems from the detection step; the enzymes used as the catalysts for the color 
precipitation of the chromogen substrate are horseradish peroxidase (HRP) and AP.  
Step 6- Primary antibody detection through direct and indirect methods, is the most 
crucial step in the IHC staining process, the other steps build upon the quality of the purified 
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antibody. The decision of monoclonal or polyclonal antibody use is determined by the abundance 
of infectious agents or the severity of tissue damage and target expression associated with the 
disease in question, in addition to the availability of commercial or in house reagents. Antibody 
paratope and antigen epitope binding motifs may require amplification for increased localized 
visualization by means of a secondary antibody.  Enzyme labeled secondary antibodies bind to 
unlabeled primary, resulting in the amplification of the binding sites and increased detection 
sensitivity (Frank, 2002; ThermoFisher, 2021). 
An enzymatic polymer chain conjugated to the secondary antibody can further amplify 
immunoreactivity at sites of primary antibody-antigen binding motifs. Due to the specificity of 
the polymer-based detection system, dual antigen labeling and IHC multiplex staining is 
achievable, reducing the final staining procedure process (Vector labs, 2021).  
Step 7- Signaling binding motif sites are subsequently visualized through a chromogen 
substrate and enzyme probe reporter colorimetric reaction. After the reporter enzyme is added 
(AP or HRP) it binds to the secondary polymer, building a backbone of amplification sites that 
will catalyze the precipitation of chromogen resulting in a colorimetric reaction at the antibody-
antigen binding site (ThermoFisher, 2021). 
Step 8- Counterstain is utilized after the detection method to obtain contrast of signal and 
highlight chromogen deposition. An example of a commonly used counterstain is hematoxylin, a 
nucleic acid stain.  






Figure 3 IHC Standardized protocol development process schematic 
 
 1.3 Dual staining vs. Single staining of tumor antigens 
Immunohistochemical techniques were developed for the detection of a single target 
antigen, it was not until the last decade that the demand for dual staining appeared due to the 
correlative informational data it provided. Dual IHC staining enables visualization of co-
localized biological markers in a tissue section by binding to two different target antigens, 
identifying multiple epitope regions. Clinical pathologists rely on accurate and timely IHC 
laboratory methods to evaluate molecular interaction and reach a diagnosis, hence the increase 
for improved IHC development techniques and tests (Dixon et al., 2015). Due to the complexity 
and specificity associated with dual IHC staining, fundamental protocol development and 
molecular biological immunoreactive knowledge is essential to success. The elimination of 
antibody cross-reactivity in correlation with specified reporter dyes is accomplished by 
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determining isotype, clonality and host species for both antibodies utilized in the dual stain 
(Dixon et al.,2015).  The respective antibodies can be stained sequentially or simultaneously, 
depending on automated stainer capabilities, antibody cross-reactivity and staining pattern 
intensity requirements (Dixon et al., 2015).   
 
 1.4 Viral IHC detection - African Swine Fever Virus 
African Swine Fever Virus (ASFV) is a highly contagious arboviral hemorrhagic disease 
that affects domestic and feral pigs with a high mortality rate for which there is no current 
vaccine, subsequently spreading throughout Africa, Asia, and Europe. ASF is considered an 
agriculture transboundary disease threat to the U.S. The viral pathogen is a highly stable DNA 
enveloped virus, remaining in infected animal by-products and the environment, presenting an 
additional route of exposure through the spread of fomites (Guinat et al., 2016). 
Immunohistochemical detection allows for visualization of antigen distribution through 
infected tissues, demonstrating pathogenicity and disease characteristics deficient in other 
laboratory detection methods. ASFV can be detected in the cytoplasm of infected host 
macrophages and monocytes during late stages of viral replication by IHC (Dixon, Islam, Nash, 
& Reis, 2019; McCullough, 1990). Lymphoid infected tissues such as: spleen, tonsil, and lymph 
nodes, should take precedence when considering IHC as the viral detection tool, due to the 
abundance of peripheral immune cells, especially macrophages.  
 
 1.5 Bacterial IHC detection – Ehrlichia ruminantium  
Heartwater, is a vector-borne disease caused by the obligate intracellular bacterium: 
Ehrlichia ruminantium. It primarily infects ruminant species throughout Africa and parts of the 
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Caribbean. E. ruminantium is classified under the order of Rickettsiales and family 
Anaplasmataceae (Allsopp, 2015; Dumler et al., 2001). The current prevention methods for E. 
ruminantium infectious are immunization, antibiotics, vector control and breed resistance; each 
method presenting separate challenges. The only current available vaccine for E. ruminantium is 
a live attenuated vaccine derived from infected sheep blood which must be cryopreserved and 
administered intravenously (Allsopp, 2015, Neitz & Alexander, 1945). The reliance on 
antibiotics as an effective treatment is likely to lead to resistance (Allsopp, 2015). Detection 
methods utilized for identification of E. ruminantium are typically molecular based due to the 
variable concentrations of bacterial antigens within a respective biological tissue sample, 
resulting in the relatively elusive identification and detection of E. ruminantium through 
immunohistochemical techniques (Jardine, Vogel, van Kleef, & van der Lugt, 1995; Brown & 
Skowronek, 1990). Additionally, utilizing IHC as a pathological diagnostic tool provides a 
testing method to remote areas deprived of laboratory facilities or tools, requiring the 
preservation of biological tissue samples for future diagnostics (Jardine et al., 1995). 
 
 1.6 Prion IHC detection - Chronic Wasting Disease 
Transmissible spongiform encephalopathies (TSEs) encompass a spectrum of fatal 
neurodegenerative diseases that are caused by the hosts cellular prion proteins (PrP) which have 
undergone a conformational change (Kupfer, Hinrichs, & Groschup, 2009). The newly misfolded 
prion protein is the proteinaceous causative agent of all prion-related diseases, found in both 
humans and animals. Human prion disease result in Creutzfeldt–Jakob disease (CJD) and Variant 
CJD (vCJD) while animals are affected by Bovine Spongiform Encephalopathy (BSE) or “Mad 
cow disease” in bovine, Scrapie in ovine species and Chronic Wasting disease (CWD) in 
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Cervidae. (32 Lee, 2013) BSE is classified as a zoonotic disease while scrapie and CWD are a 
concern for zoonotic potential, categorizing prion diseases as reportable (USDA, APHIS, 2020). 
Prions are extremely stable infectious particles, allowing them to persist in a host or environment 
for years while remaining resistant to all forms of disinfectant, with incineration as the only 
confirmed method of decontamination for all known prion strains (USDA, APHIS, 2020; 
Saunders, Bartelt-Hunt, & Bartz, 2008). Due to limited understanding of the tertiary misfolding 
and pathogenesis of infectious prions, detection methods present difficulties, establishing IHC as 
the gold standard of CWD and Scrapie testing (USDA, APHIS, 2020). Current USDA testing 
standards for prion diseases require a postmortem IHC of the dorsal nucleus of the Vagus nerve 
located in the obex of the brainstem in addition to the follicular regions of the medial 






Chapter 2 – Methodology 
2.1 Introduction - IHC Dual stain detection of CD3/ PAX-5  
CD3 or cluster of differentiation 3, is a T cell co-receptor protein complex that aids in the 
activation of naïve CD8+ cytotoxic T cells and CD4+ helper T cells. (Janeway et al., 2001) 
CD3 is expressed at all stages in the T cell development process, therefore establishing its 
importance as an IHC marker for pathological diagnosis of lymphoproliferative disorders and 
neoplastic tumors of T cell origin within tissue sections (Salvadori, Gansbacher, Pizzimenti, & 
Zier, 1994; Vernau & Moore 1999).  
PAX5 is a B cell activator protein transcription factor which stimulates activation, 
proliferation, and differentiation of the B-lineage cell line (Jensen et al., 2007; Palmisano et al., 
2003; Schafer, 1998). The PAX5 protein is specifically expressed as a nuclear marker and is 
detectable during the early stages of the B cell maturation process but remains undetectable in 
mature plasma cells. (Desouki, Post, Cherry, & Lazarchick, 2010; Adams et al., 1992; Horcher, 
Souabni, & Busslinger, 2001; Krenacs et al., 1998). For these reasons PAX5 is commonly used 
as an IHC molecular marker for not only the detection of B cell neoplasms but subclassification 
identification of lymphomas establishing lineage specific traits (Feldman & Dogan, 2007).  
The combination of CD3 and PAX5 as a dual IHC stain for lymphoproliferative disorders 
has the potential to demonstrate co-localization of specific antigen expression within associated 
cells. The use of a dual B and T cell biomolecular target method, would provide pathologists 
with informative disease characteristics and in conjunction, decrease interpretation and diagnosis 




 2.1.1 Dual staining - Materials and Methods 
Soft tissue sections from canine lymph nodes were trimmed and fixed using 10% neutral 
buffered formalin (NBF) and processed for immunohistochemistry using the Sakura Tissue Tek 
VIP 6 processor. The paraffin embedded lymphoid tissues were cut on a microtome at 4 microns 
and placed onto positively charged slides then left to dry overnight at 37℃ to ensure tissue 
adherence. Slides were stained using a Leica Bond RXm automated research stainer. Slides were 
deparaffinized at 72℃ for 30 seconds. Antigen retrieval was performed using an EDTA heat 
induced epitope retrieval (HIER) solution with a pH of 9.0 (Leica Biosystems Epitope Retrieval 
2) at 100.0°C for 20 minutes followed by a 3% hydrogen peroxide block for 5 minutes. The 
slides were then incubated with the first antibody of the dual stain: CD3 mouse monoclonal 
antibody (Leica Biosystems, clone LN10) for 15 minutes at 15-25℃ followed by a 
polymerization step with PowerVision Poly- Horseradish Peroxidase (HRP) anti-mouse IgG 
conjugate (Leica Biosystems Inc., IL), for 15 minutes at room temperature. Color precipitate was 
developed with Diaminobenzidine (DAB) chromogenic substrate (Leica Biosystems Refine Kit) 
system for 10 minutes. Omission of counterstain and peroxidase steps prior to addition of 
subsequent PAX5 antibody. Second antigen retrieval preparation step using a Citrate HIER with 
a pH of 6.0 (Leica Biosystems Epitope Retrieval 1), incubated for 20 minutes at 100.0°C. PAX5 
rabbit monoclonal antibody (ChampDx, clone CHMP0307) diluted 1:300 in Bond Primary 
Antibody Diluent (Leica Biosystems), was added to the slides and incubated for 15 minutes at 
room temperature. Polymerized with PowerVision Poly- Alkaline Phosphatase (AP) anti-rabbit 
IgG conjugate (Leica Biosystems Inc., IL), for 15 minutes at room temperature. Visualization 
through Fast Red chromogenic substrate (Leica Biosystems Red Refine Kit) for 15 minutes and 
counterstained with Hematoxylin. 
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For comparison, the same protocol was carried out, altering the antibody sequence only 
to determine the effects, if any, that DAB and Fast Red demonstrate when placed over one 
another. Additional single marker CD3 and PAX5 comparison control stains were run 
simultaneously for pathological baseline verification of the dual staining. Slides were digitally 
scanned at 40x magnification using Aperio AT2 digital scanner and uploaded with eSlide 
Manager (Leica Biosystems Inc., IL).  
 
 2.2 Viral - African Swine Fever Virus – Materials and Methods 
PCR confirmed ASFV positive lung samples in addition to experimental splenic tissues 
were fixed in 10% NBF, processed with paraffin, embedded, and cut at 4 microns. The tissue 
sections were then placed on positively charged slides and incubated at 37℃ until completely 
dry. Staining of the slides were conducted on a Leica Bond RXm automated research stainer. 
Slides were deparaffinized at 72°C for 30 seconds. Antigen retrieval was performed using an 
EDTA HIER solution with a pH of 9.0 (Leica Biosystems Epitope Retrieval 1) at 100.0°C for 20 
minutes followed by a 3% hydrogen peroxide block for 5 minutes. The slides were then 
incubated with primary mouse anti-ASFV p30 monoclonal antibody at a 1:100 dilution for 15 
minutes at room temperature followed by a polymerization step with PowerVision Poly-AP anti-
mouse IgG conjugate (Leica Biosystems Inc., IL), for 15 minutes at room temperature. Color 
precipitate was developed through Fast Red chromogenic substrate (Leica Red Refine Kit) for 15 
minutes and counterstained with Hematoxylin.  
The protocol was replicated using a 1:300 dilution to determine background or 
endogenous antibody binding for pathological interpretation. Additionally, biological and 
reagent negative controls were conducted simultaneously for viral staining characteristic 
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verification. Slides were digitally scanned at 40x magnification using Aperio AT2 digital scanner 
and uploaded with eSlide manager (Leica Biosystems Inc., IL).  
 
 2.3 Bacterial - Ehrlichia ruminantium – Materials and Methods 
Experimental lung tissue samples from sheep were processed according to histological 
standards for immunohistochemical staining. All staining was conducted on a Leica Bond-Max 
automated research stainer. Slides were deparaffinized at 72°C for 30 seconds, directly followed 
by antigen retrieval performed with a Citrate HIER solution with a pH of 6.0 (Leica Biosystems 
Epitope Retrieval 1) at 100.0°C for 20 minutes followed by a 3% hydrogen peroxide block for 5 
minutes. The slides were then incubated with an in-house polyclonal canine sera primary 
antibody for E. ruminantium at a 1:100 dilution for 15 minutes at room temperature followed by 
an anti-canine secondary-HRP conjugated antibody at a 1:500 dilution for an additional 15 
minutes at room temperature. Color precipitate was developed with DAB+ chromogenic 
substrate (Leica Refine Kit) system for 10 minutes. A biological negative control was run in 
conjunction with three reagent negative controls consisting of a primary only, secondary only 
and a complete negative reagent. Due to the nature of in-house antibodies, additional verification 
was required to corroborate the immunoexpression and pathological associated etiology of the 
target agent.  
 
 2.4 Prion – Chronic Wasting Disease - Materials and Methods 
Confirmed CWD positive obex and lymph node cervid tissues were fixed in 10% NBF, 
processed and paraffin embedded. Sections were taken at 5 microns, placed on positively 
charged slides and dried at 37℃ overnight. Slides were incubated at 80℃ for 15 minutes and 
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exposed to a series of xylene and ethanol baths for deparaffinization, once complete, the slides 
were placed in 88% formic acid for 5 minutes followed by a pH correcting step of Tris Buffer 
with a pH of 7.5 over three washes. Antigen retrieval step was conducted in a decloaker 
(Biocare) for 20 minutes at 120℃ at 21-25 PSI range, with a cool down period of 25 minutes. 
Slides were placed in bond buffer wash and staining was conducted on a Leica Bond-Max 
automated stainer. The slides were incubated with F99 Prion antibody (VMRD) at a 1:500 
dilution with Leica IHC/ISH Super Blocker 110 reagent for 30 minutes at room temperature 
followed by a polymerization step with PowerVision Poly-AP anti-mouse IgG conjugate (Leica 
Biosystems Inc., IL), for 10 minutes at room temperature. Color precipitate was developed 
through Fast Red chromogenic substrate (Leica Red Refine Kit) for 15 minutes and 
counterstained with Hematoxylin. Comparative slides were incubated in Tris buffer with a pH of 
6.5 following the inactivation step. Slides were run simultaneously to establish the effects of pH 
on overall staining pattern. Additionally, biological negative controls were required for 
pathological verification. Slides were digitally scanned at 40x magnification using Aperio AT2 












 3.1 CD3-PAX5 Dual staining results  
Antibody compatibility selection of the B/T-cell biomarker targets determined prior to 






Figure 4 CD3 and PAX5 single staining IHC method on canine lymph node tissue sections. 
(A) CD3 staining (T cell marker) with Leica RTU, Refine DAB/HRP, Monoclonal Mouse 
antibody. CD3 antibody is a RTU reagent and is formulated to be used in direct correlation with 
the Leica DAB/HRP kit. The CD3 cytoplasmic immunoreactivity appearance was scored as 
positive and negative. (B) PAX5 staining (B cell marker) on lymph node with Champ DX 
Monoclonal Rabbit antibody with Refine Red/Alkaline Phosphatase. The PAX5 nuclear 

















Figure 5 : CD3 PAX5 Dual sequential staining IHC method on canine lymph node tissue 
sections. 
(A) CD3-HRP staining followed by PAX5-AP (20 minutes HIER incubation method set for 
initial and secondary staining, respectively. (B) CD3-HRP staining followed by PAX5-AP with 
reduced initial HIER incubation (10 minutes HIER incubation method set for initial CD3 
staining with maintained 20 minutes HIER incubation of PAX5. (C) Order of sequential staining 
altered, PAX5-AP staining followed by CD3-HRP (20 minutes HIER incubation method set for 












 3.2 ASFV staining results 
Positive ASFV was detected in both lung and splenic tissues, viral antigen characteristics 
demonstrated peak signal to noise ratio at a primary antibody dilution factor of 1:300 in lung 
tissue and 1:100 in splenic tissue.   
 
 
Figure 6 : IHC staining of ASFV in porcine spleen and lung tissues utilizing p30 
monoclonal antibody in conjunction with AP/Fast Red for visualization. 
(A) Experimental splenic tissue, p30 antibody dilution factor of 1:100 visualized with AP/Fast 
red (B) Experimental splenic tissue, p30 antibody dilution factor of 1:100 visualized with 
AP/Fast red. (C) Lung tissue utilized as development control, p30 antibody dilution factor of 
























 3.3 Ehrlichia ruminantium staining results 
Targeted staining detected in lung sections eliminated as E. ruminantium based reagent 
control and bacterial characteristics. Blocking of endogenous peroxidases was pursued to 
determine cause of staining.  
 
Figure 7 : E. ruminantium IHC staining in sheep lung tissue, visualized with DAB/HRP. 
(A) 1:500 dilution, pre-treatment of Proteinase K. (B) 1:500 dilution with HIER pre-treatment 
with EDTA pH (9). (C) 1:500 dilution with HIER pre-treatment with Citrate pH (6). (D) Reagent 
negative control with HIER pre-treatment with Citrate pH (6). (E) Peroxidase blocking step prior 
to addition of chromogen. (F) Non-specific staining (G) & (H) Positive IHC staining of E. 
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ruminantium in sheep brain tissue, (Section of Pathology, Department of Paraclinical Sciences, 
Faculty of Veterinary Science, University of Pretoria). 
 
 3.4 Prion- Chromic Wasting Disease staining results 
Positive CWD staining was demonstrated in both the obex and submandibular lymphoid 
follicles as shown in Figures 8-9. The positive staining intensity decreased when exposed to a 






Figure 8 CWD prion IHC staining in cervid submandibular lymphoid tissue with F99 
antibody and AP/Fast Red for visualization. 
(A) Strong CWD positive staining visualized in lymphoid follicles utilizing Tris Buffer with a 
pH of 7.5 in staining process. (B) Visibly diminished CWD positive staining in lymphoid 


















Figure 9 CWD prion IHC staining in cervid brainstem (obex) tissue with F99 antibody and 
AP/Fast Red for visualization. 
(A) Strong CWD positive staining visualized in obex sections utilizing Tris Buffer with a pH of 
7.5 in staining process. (B) Visibly diminished CWD positive staining in obex sections utilizing 





















4.1 Dual staining discussion 
As shown in Figures 4-5, CD3 and PAX5 demonstrate their effectiveness as comparative 
T and B cell compatible biomarkers, respectively, through robust and distinctive staining 
patterns, providing additional pathological information while minimizing interpretive analysis. 
Chromogenic staining intensity exhibited modifiable expression through antigen retrieval 
incubation periods, as demonstrated in Figure 5 (B). Due to DAB’s superior insolubility, it was 
chosen as the first antigen biomarker target. Histological comparative analysis demonstrated 
strong independent CD3 and PAX5 staining in comparison to Fast Red as the initial target 
identifier in the dual detection process. Dual staining provided co-localized B and T-cell 
distribution patterns as well as comprehensive cell lineage insight within the tissue matrix, absent 
in single target use, illustrating multifunctional uses of dual staining. Ensuring antibody 
compatibility is essential to success of dual staining and perhaps the greatest challenge 
associated with the development process.  
 
4.2 Viral IHC detection - African Swine Fever Virus discussion 
ASFV infected porcine lung and spleen tissue sections exhibited variable viral antigen 
expression from differing immunological responses from host and tissue type, altering IHC 
primary antibody dilution. Figure 6 demonstrates true staining of ASFV viral antigens within the 
cytoplasm of the cell. Implementing a strategic standardized approach to the development of p30 
antibody, reduced excess antibody and reagent waste during the protocol development process. 
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Visualization of p30 and viral antigen biomolecular binding was modified based on tissue target 
and subsequently the primary antibody dilution factor.  
4.3 Bacterial IHC detection - Ehrlichia ruminantium discussion 
E. ruminantium bacteria replicate within the cytoplasm of the hosts endothelial cells, 
predominantly in the lungs and myocardium of the infected ruminant species (Jardine, 1995). 
The pathological staining analysis of the experimental HRP-conjugated antibody performed on 
lung tissue proved to be false staining. A combination of endogenous protein expression and 
staining reagents utilized, produced non-specific DAB binding visualization deviating from 
characteristic E. ruminantium bacterial pathogenesis, as demonstrated in Figure 7. The biological 
and reagent negative controls ran simultaneously, exhibited comparable punctate staining as 
demonstrated in the experimental lung sections, augmenting the false-positive diagnostic 
analysis. The E. ruminantium experimental antibody development illustrates the importance of 
collaborating with a diagnostic pathologist in addition to incorporating appropriate 
developmental controls to ensure the validity of an IHC tests. 
 
4.4 Prion IHC detection - Chronic Wasting Disease discussion 
Infectious prion proteins were detected in obex and lymphoid tissue sections of naturally 
infected cervids as shown in Figures 8-9. IHC testing is sensitive with an exorbitant number of 
factors influencing staining outcome, directly affecting the qualitative analysis should target 
staining expression diminish, resulting in potential misdiagnoses. Pre-determined steps critical to 
the staining process could improve identification of causation for weakened staining; pH of 
reagents involved in antigen retrieval of sequestered epitopes being among the most prominent in 
CWD staining.  CWD has an extended incubation period and animals in the early stages of the 
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disease may exhibit low levels of infectious prions. Weakened IHC staining in correlation with 
low infectious biomolecular expression levels increases the probability of a misdiagnosis by the 
pathologist. Obtaining a strong antibody-antigen binding signal with clean background staining 
is a continuous balancing act for all IHC developmental and subsequent tests, particularly 
regarding prion testing. The conformational protein folding patterns of infectious prions present 
additional challenges requiring subsequent protocol steps for successful staining. Improved 
quality of overall staining can be achieved by knowledge of critical sensitive steps and 





















IHC has established itself as a reliable and efficient diagnostic tool with exemplary 
specificity in identification of infectious biomolecular expression and cell types in FFPE tissue 
sections. Relying on biomolecular manipulation, IHC is sensitive to a multitude of factors, 
presenting a challenge with respect to development of new and improved IHC tests. The 
implementation of a strategic standardized approach for IHC protocol development is essential to 
diminishing protocol development associated costs and diagnosis turnaround time while 
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 Glossary of Terms 
IHC- Immunohistochemistry 
FFPE- Fixed-formalin paraffin-embedded  
HIER- Heat Induced Epitope Retrieval  
HRP- Horseradish Peroxidase 
AP- Alkaline Phosphatase 
ASFV- African Swine Fever Virus 
TSE’s- Transmissible spongiform encephalopathies  
CWD- Chronic Wasting Disease 
PrP- Prion protein 
CJD- Creutzfeldt–Jakob disease  
vCJD- Variant CJD  
BSE- Bovine Spongiform Encephalopathy 
NBF- Neutral buffered formalin  
EDTA- Ethylenediaminetetraacetic acid 
DAB- Diaminobenzidine 
 
  
 
 
 
